Logo image of CYAD.BR

CELYAD ONCOLOGY (CYAD.BR) Stock Fundamental Analysis

EBR:CYAD - BE0974260896 - Common Stock

0.309 EUR
0 (-0.32%)
Last: 9/4/2025, 7:00:00 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CYAD. CYAD was compared to 74 industry peers in the Biotechnology industry. Both the profitability and financial health of CYAD have multiple concerns. While showing a medium growth rate, CYAD is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CYAD had negative earnings in the past year.
In the past year CYAD has reported a negative cash flow from operations.
In the past 5 years CYAD always reported negative net income.
CYAD had a negative operating cash flow in each of the past 5 years.
CYAD.BR Yearly Net Income VS EBIT VS OCF VS FCFCYAD.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

CYAD has a worse Return On Assets (-58.66%) than 67.57% of its industry peers.
Looking at the Return On Equity, with a value of -1139.73%, CYAD is doing worse than 74.32% of the companies in the same industry.
Industry RankSector Rank
ROA -58.66%
ROE -1139.73%
ROIC N/A
ROA(3y)-106.06%
ROA(5y)-75.47%
ROE(3y)-740.65%
ROE(5y)-467.64%
ROIC(3y)N/A
ROIC(5y)N/A
CYAD.BR Yearly ROA, ROE, ROICCYAD.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

CYAD's Gross Margin of 93.55% is amongst the best of the industry. CYAD outperforms 90.54% of its industry peers.
CYAD's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for CYAD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 93.55%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-1.32%
CYAD.BR Yearly Profit, Operating, Gross MarginsCYAD.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200K -400K -600K -800K

More info and screens

3

2. Health

2.1 Basic Checks

CYAD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CYAD has about the same amount of shares outstanding.
The number of shares outstanding for CYAD has been increased compared to 5 years ago.
The debt/assets ratio for CYAD is higher compared to a year ago.
CYAD.BR Yearly Shares OutstandingCYAD.BR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
CYAD.BR Yearly Total Debt VS Total AssetsCYAD.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

CYAD has an Altman-Z score of -2.13. This is a bad value and indicates that CYAD is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -2.13, CYAD is not doing good in the industry: 62.16% of the companies in the same industry are doing better.
CYAD has a Debt/Equity ratio of 1.49. This is a high value indicating a heavy dependency on external financing.
CYAD has a worse Debt to Equity ratio (1.49) than 64.86% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.49
Debt/FCF N/A
Altman-Z -2.13
ROIC/WACCN/A
WACC7.34%
CYAD.BR Yearly LT Debt VS Equity VS FCFCYAD.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

CYAD has a Current Ratio of 2.29. This indicates that CYAD is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.29, CYAD is in line with its industry, outperforming 52.70% of the companies in the same industry.
CYAD has a Quick Ratio of 2.14. This indicates that CYAD is financially healthy and has no problem in meeting its short term obligations.
CYAD has a Quick ratio of 2.14. This is in the better half of the industry: CYAD outperforms 60.81% of its industry peers.
Industry RankSector Rank
Current Ratio 2.29
Quick Ratio 2.14
CYAD.BR Yearly Current Assets VS Current LiabilitesCYAD.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 57.23% over the past year.
The Revenue has grown by 82.35% in the past year. This is a very strong growth!
The Revenue has been growing by 98.73% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)57.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.88%
Revenue 1Y (TTM)82.35%
Revenue growth 3YN/A
Revenue growth 5Y98.73%
Sales Q2Q%196.55%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CYAD.BR Yearly Revenue VS EstimatesCYAD.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2023 2024 2M 4M 6M 8M
CYAD.BR Yearly EPS VS EstimatesCYAD.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CYAD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYAD.BR Price Earnings VS Forward Price EarningsCYAD.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYAD.BR Per share dataCYAD.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.05 -0.1 -0.15 -0.2 -0.25

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CYAD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CELYAD ONCOLOGY

EBR:CYAD (9/4/2025, 7:00:00 PM)

0.309

0 (-0.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-02 2025-04-02/amc
Earnings (Next)09-25 2025-09-25
Inst Owners55.35%
Inst Owner ChangeN/A
Ins Owners0.51%
Ins Owner ChangeN/A
Market Cap6.98M
Analysts42.22
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 37.54
P/FCF N/A
P/OCF N/A
P/B 13.66
P/tB 65.86
EV/EBITDA N/A
EPS(TTM)-0.14
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS0.01
BVpS0.02
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -58.66%
ROE -1139.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 93.55%
FCFM N/A
ROA(3y)-106.06%
ROA(5y)-75.47%
ROE(3y)-740.65%
ROE(5y)-467.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-1.32%
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 1.49
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.22%
Cap/Sales 63.44%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.29
Quick Ratio 2.14
Altman-Z -2.13
F-Score3
WACC7.34%
ROIC/WACCN/A
Cap/Depr(3y)50.8%
Cap/Depr(5y)39.13%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.88%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)82.35%
Revenue growth 3YN/A
Revenue growth 5Y98.73%
Sales Q2Q%196.55%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y30.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y64.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y62.64%
OCF growth 3YN/A
OCF growth 5YN/A